Keytruda Pembrolizumab For Mesothelioma, Fda Approval Of Keytruda Will Help Some Mesothelioma Patients

Pembrolizumab often known by the brand name keytruda is a well known immunotherapy drug already being used with mixed success for several cancers.

Images of asbestos shingles. The drug has not received us. Doctors and researchers use keytruda in combination with traditional mesothelioma treatments such as surgery and chemotherapy. Keytruda did not improve progression free survival for mesothelioma patients who progressed after first line chemotherapy.

Food and drug administration approval for treatment of malignant mesothelioma cancer but has shown promise in extending life expectancy through clinical trials. Keytruda has shown improved survival among mesothelioma patients in clinical trials. Patients with pleural mesothelioma cancer may have another treatment option after the us.

Mesothelioma affects mainly the thin protective lining tissue that covers the lungs and abdomen. At a recent medical conference researchers revealed discouraging news about the immunotherapy drugs effectiveness treating this disease on its own. The united states food and drug administration fda approved the brand name immunotherapy drug for specific cases of pleural mesothelioma among other solid tumor cancers.

Keytruda pembrolizumab is an immunotherapy drug developed by merck and approved to treat certain advanced types of cancers such as non small cell lung cancer nsclc melanomas and head and neck cancer. Keytruda is an immunotherapy drug that is designed to boost the immune system causing an anti cancer effect that can help the body kill cancer cells ultimately working to treat cancers like malignant mesothelioma. Food and drug administration approved the use of pembrolizumab for certain metastatic tumors this week.

However not all hope is lost for keytruda as a viable mesothelioma treatment. Food and drug administration fda based on cancer genetics. Keytruda the brand name for pembrolizumab has been a source of hope for many people with mesothelioma.

For people affected by asbestos exposure keytruda is exciting because early studies suggest it may be a useful chemotherapy drug for mesothelioma. Keytruda pembrolizumab is approved to treat cancers with a specific biomarker the first drug to be approved by the us. Keytruda pembrolizumab is an immunotherapy drug that works for malignant mesothelioma by unmasking tumor cells and allowing the immune system to fight cancer.

Keytruda also known by its generic name pembrolizumab has been approved to treat non small cell lung cancer nsclc melanoma and head and neck squamous cell cancer hnscc among other cancers. The drug is also being tested for the treatment of mesothelioma a rare type of cancer with no known cure. The fdas approval occurred tuesday june 16 2020.